 |
市场调查报告书
商品编码
1378701
復发或难治性瀰漫性大 B 细胞淋巴瘤市场：按药物类型、配销通路和地区划分Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, By Distribution Channel, By Geography |
||||||
预计到 2023 年，全球復发或难治性瀰漫性大 B 细胞淋巴瘤市场将达到 14.795 亿美元，预计在预测期内（2023-2030 年）年复合成长率为 4.3%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2022年 | 2023年市场规模 | 14.795 亿美元 |
| 实绩资料 | 2018-2021 | 预测期 | 2023-2030 |
| 预测期年复合成长率 | 4.30% | 2030年市场规模预测 | 19.864 亿美元 |
瀰漫性大 B 细胞淋巴瘤 (DLBCL) 是最常见的淋巴瘤，约占所有非何杰金氏淋巴瘤的 25% 至 30%。此疾病表现为结节或结外部位迅速增大的肿块或淋巴结肿大。儘管具有攻击性，但它对化疗反应良好。它会影响许多器官系统，最好由包括肿瘤内科医师、放射肿瘤科医师和肾臟科医师在内的专家团队进行管理。结外淋巴瘤可能需要放射线治疗。淋巴瘤患者常报告肾臟受累。在病程早期让肾臟科医师介入非常重要，因为肾衰竭可能是 DLBCL 本身的併发症，也可能在治疗期间出现。应仔细评估酸碱、电解质和液体量等肾臟指标。具有不同技术基础和作用机制的新药的推出将有助于市场的扩大。因此，此类先进产品的市场引入预计将在预测期内推动全球復发或难治性瀰漫性大 B 细胞淋巴瘤市场的成长。
市场动态
製药业的主要参与者专注于开髮用于治疗復发或难治性瀰漫性大 B 细胞淋巴瘤的平台药物。因此，将此类先进产品引入市场预计将在预测期内推动全球復发或难治性瀰漫性大B细胞淋巴瘤市场的成长。例如，2023年9月29日，领先的生技公司再生元製药公司（Regeneron Pharmaceuticals, Inc.）宣布，美国食品食品药物管理局（FDA）已确认，美国食品药物管理局（FDA）已确认患有復发/至少两次全身治疗后出现进展的难治性 (R/R) 卵泡宣布，其 odronextamab 的生技药品核准申请(BLA) 已收到优先审查，用于治疗患有性淋巴瘤(FL ) 或R/R 瀰漫性大成人患者B 细胞淋巴瘤 (DLBCL)。 FDA 的决定目标日期是 2024 年 3 月 31 日。 Odronextamab 是一种 CD20xCD3 双特异性抗体，旨在在桥接癌细胞上表达 CD20 和 CD3 的 T 细胞，促进局部T 细胞活化和癌细胞杀伤。这是一种临床实验药物。
本研究的主要特点
- 本报告对全球復发或难治性瀰漫性大 B 细胞淋巴瘤市场进行了详细分析，并介绍了以 2022 年为基准年的预测期（2023-2030）的市场规模和年复合成长率。
- 它还阐明了不同细分市场的潜在商机，并解释了该市场有吸引力的投资提案矩阵。
- 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
- 该报告根据公司亮点、产品系列、主要亮点、业绩和策略等参数，介绍了全球復发或难治性瀰漫性大 B 细胞淋巴瘤市场的主要参与者。
- 该报告的见解将使行销人员和经营团队负责人就未来的产品发布、升级、市场扩张和行销策略做出资讯的决策。
- 全球復发或难治性瀰漫性大 B 细胞淋巴瘤市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 相关人员可以透过用于分析全球復发或难治性瀰漫性大 B 细胞淋巴瘤市场的各种策略矩阵来促进决策。
目录
第1章调查目的和假设
- 研究目标
- 假设
- 简称
第2章市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map（COM）
第3章市场动态、法规及趋势分析
- 市场动态
- 促进因素
- 抑制因素
- 市场机会
- 影响分析
- 最近的趋势
- 最近的产品发布/核准
- 合併、收购和合作
- 监管场景
- 主要进展
- PEST分析
- 波特的分析
第4章全球復发或难治性瀰漫性大B细胞淋巴瘤市场-新型冠状病毒感染疾病（COVID-19）的影响分析
- 经济影响
- 新型冠状病毒感染疾病（COVID-19）的流行病学
- 对需求和供给的影响
第5章2018-2030 年全球復发或难治性瀰漫性大 B 细胞淋巴瘤市场（依药物类型）
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- 其他的
第6章全球復发或难治性瀰漫性大 B 细胞淋巴瘤市场（按配销通路），2018-2030 年
- 医院药房
- 零售药房
- 线上药房
第7章2018-2030年全球復发或难治性瀰漫性大B细胞淋巴瘤市场（按地区）
- 北美洲
- 美国
- 加拿大
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中东
- GCC
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第8章竞争形势
- 公司简介
- MorphoSys US Inc.
- Bristol-Myers Squibb Company
- Karyopharm Therapeutics
- F. Hoffmann-La Roche AG
- Merck &Co., Inc.
- Gilead Sciences, Inc.
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Cellular Biomedicine Group Inc.
- Genmab A/S
- Incyte
- AbbVie Inc.
- Janssen Biotech, Inc.
- Pfizer Inc.
- IMV Inc.
- Overland Pharmaceuticals（CY）Inc.
- ADC Therapeutics SA
- Eagle Pharmaceuticals, Inc.
- Adaptive Biotechnologies Corporation
- 分析师观点
第9章章节
- 参考
- 调查方法
Global relapsed or refractory diffuse large B cell lymphoma market is estimated to be valued at US$ 1,479.5 Mn in 2023 and is expected to exhibit a CAGR of 4.3% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 1,479.5 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 4.30% | 2030 Value Projection: | US$ 1,986.4 Mn |
Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma that account forabout 25% to 30% of all non-Hodgkin lymphoma. This disease presents as a rapidly growing mass or enlarging lymph nodes in a nodal or extranodal site. Though aggressive, it does respond well to chemotherapy. It can affect many organ systems, and is best managed by an interprofessional team including the medical oncologist, radiation oncologist, and nephrologists. Radiation therapy can be needed in extranodal lymphomas. Kidney involvement has been well documented in patients with lymphoma. It is important to get the nephrologist involved early in the course of the disorder as renal failure is a complication of DLBCL itself, or renal failure can manifest during treatment. Careful assessment of the renal indices including acid-base, electrolytes, and volume status, should be assessed. The introduction of new drug with different technological platform and Mechanism of Action can contribute to market expansion. Thus, introduction of such advanced products in the market is expected to drive growth of the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period.
Market Dynamics
The key players in the pharmaceutical industry are focusing on development of platform based drug for relapsed or refractory diffuse large B cell lymphoma. Thus, introduction of such advanced products in the market is expected to drive growth of the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period. For instance, on September 29, 2023, Regeneron Pharmaceuticals, Inc., a leading biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had accepted for Priority Review the Biologics License Application (BLA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. The target action date for the FDA decision is March 31, 2024. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
Key features of the study:
- This report provides an in-depth analysis of the global relapsed or refractory diffuse large B cell lymphoma market and provides market size (US$ Mn ) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global relapsed or refractory diffuse large B cell lymphoma market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include MorphoSys U.S. Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F.Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., Novartis AG, Regeneron Pharmaceuticals, Cellular Biomedicine Group Inc., Genmab A/S, Incyte, AbbVie Inc., Janssen Biotech, Inc., Pfizer Inc., IMV Inc., Overland Pharmaceuticals (CY) Inc., ADC Therapeutics SA, Eagle Pharmaceuticals, Inc., and Adaptive Biotechnologies Corporation
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global relapsed or refractory diffuse large B cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global relapsed or refractory diffuse large B cell lymphoma market
Detailed Segmentation:
- By Drug Type:
- Monjuvi
- XPOVIO
- Polivy
- Kymriah
- Yescarta
- Others
- By Distribution Channel:
- Hospitals Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- MorphoSys U.S. Inc.
- Bristol-Myers Squibb Company
- Karyopharm Therapeutics
- F. Hoffmann-La Roche AG
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- Novartis AG
- Regeneron Pharmaceuticals
- Cellular Biomedicine Group Inc.
- Genmab A/S
- Incyte
- AbbVie Inc.
- Janssen Biotech, Inc.
- Pfizer Inc.
- IMV Inc.
- Overland Pharmaceuticals (CY) Inc.
- ADC Therapeutics SA
- Eagle Pharmaceuticals, Inc.
- Adaptive Biotechnologies Corporation
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Trends
- Recent Product Launches/Approvals
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- PORTER's Analysis
4. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Monjuvi
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- XPOVIO
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Polivy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Kymriah
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Yescarta
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Segment Trends
6. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Distribution Channel, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- Hospitals Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Mn)
7. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Region, 2018-2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2019-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, a By Drug Type, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- MorphoSys US Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Bristol-Myers Squibb Company
- Karyopharm Therapeutics
- F. Hoffmann-La Roche AG
- Merck & Co., Inc.
- Gilead Sciences, Inc.
- Novartis AG
- Regeneron Pharmaceuticals, Inc.
- Cellular Biomedicine Group Inc.
- Genmab A/S
- Incyte
- AbbVie Inc.
- Janssen Biotech, Inc.
- Pfizer Inc.
- IMV Inc.
- Overland Pharmaceuticals (CY) Inc.
- ADC Therapeutics SA
- Eagle Pharmaceuticals, Inc.
- Adaptive Biotechnologies Corporation
- Analysts' Views
9. Section
- References
- Research Methodology
- About us and Sales Contact
